SABCS 2023

Tucatinib combined with trastuzumab and capecitabine improved brain metastasis survival in a recent clinical trial. The combination was found to be safe and may delay the development of new brain lesions in patients with breast cancer. Treatments targeting human epidermal growth factor receptor 2  (ERBB2) significantly improve outcomes in patients with ERBB2-positive breast tumors. Despite...

In the front-line treatment of human epidermal growth factor receptor 2-positive patients, dalpiciclib with pyrotinib demonstrates promising efficacy and acceptable tolerability. A highly selective, small-molecule CDK4/6 inhibitor, palbociclib (SHR6390), was recently authorized in China for hormone receptor (HR)-positive, human epidermal growth factor receptor (HER)2-negative advanced breast cancer (ABC).  Pyrotinib is an orally administered, irreversible pan-ErbB...

Atezolizumab therapy for advanced or metastatic triple-negative breast cancer (TNBC) was found to have a similar safety profile to those of previous trials and was associated with changes to the immune system in a recent retrospective study.  Triple-negative breast cancer (TNBC) refers to breast tumors that lack hormone receptors (HR) and human epidermal growth factor...

A recent survey study concluded that to encourage metastatic breast cancer patients to exercise, individualized, accessible programs with clear instructional materials should be created. To improve patient engagement and program evaluation, there is a need for country-specific strategies, reimbursement clarification, and interdisciplinary collaboration. Despite notable progress in the early detection and therapeutic interventions for breast...

Trastuzumab deruxtecan significantly improved overall survival compared to trastuzumab emtansine in a multi-center phase 3 trial. Human epidermal growth factor receptor 2 (HEGFR 2) is overexpressed in 15–20% of breast cancers. Currentlu, for HER2-positive metastatic breast cancer, pertuzumab and trastuzumab, plus a taxane, are first-line treatments. Second-line therapy is trastuzumab deruxtecan or trastuzumab emtansine, both...

Triple-negative breast cancer patients treated with immune checkpoint inhibitors may experience a greater antitumoral immune response, according to a recent literature review. Immunotherapy, especially immune checkpoint inhibitors (ICIs), has revolutionized solid tumor malignancy treatment. ICIs target immunosuppressive receptors such as programmed cell death ligand 1 (PD-L1), programmed cell death 1 (PD-1), and cytotoxic T-lymphocyte-associated protein...

Elacestrant improves progression-free survival in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer, especially in patients with estrogen receptor 1 gene mutations, according to the results of a recent literature review. Endocrine therapy is the backbone of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer treatment. Most cases...

Racial disparities in curative intent surgery, endocrine therapy, and treatment-related adverse effects were seen among women with breast cancer in a recent single-center study. Breast cancer (BC) is the most common malignancy occurring worldwide among women. Racial disparities in BC outcomes and access to treatment are well documented, but there’s a lack of evidence regarding...

Oral selective estrogen receptor degraders are effective in the estrogen receptor 1 mutation subgroup of estrogen receptor-positive metastatic breast cancer, according to the results of a new study. Oral selective estrogen receptor degraders (SERDs) are novel agents used to treat estrogen receptor (ER)-positive metastatic breast cancer resistant to other hormonal agents. Elacestrant and camizestrant have...